2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study

BACKGROUND: Nirsevimab is an extended half-life monoclonal antibody that binds the prefusion conformation of RSV fusion (F) protein and has been approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants in the EU, Great Britain, and Cana...

Descripción completa

Detalles Bibliográficos
Autores principales: Morehouse, Christopher A, Ahani, Bahar, Aksyuk, Anastasia A, Brady, Tyler, Tuffy, Kevin M, Ji, Hong, Kelly, Elizabeth J, Wilkins, Deidre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678722/
http://dx.doi.org/10.1093/ofid/ofad500.2253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678722/
http://dx.doi.org/10.1093/ofid/ofad500.2253

Ejemplares similares